{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:34:26Z","timestamp":1792092866563,"version":"4.4.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["864815"],"award-info":[{"award-number":["864815"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1053\/j.seminhematol.2024.04.001","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T06:15:41Z","timestamp":1714198541000},"page":"163-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The complexities of T-cell dysfunction in chronic lymphocytic leukemia"],"prefix":"10.1053","volume":"61","author":[{"given":"Elena","family":"Camerini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derk","family":"Amsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-1891","authenticated-orcid":false,"given":"Arnon P.","family":"Kater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur S.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.001_bib0001","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.beha.2010.02.001","article-title":"Chronic lymphocytic leukemia: a disease of activated monoclonal B cells","volume":"23","author":"Damle","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.04.001_bib0002","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment","volume":"3","author":"de Weerdt","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.04.001_bib0003","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3324\/haematol.2016.142679","article-title":"Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk","volume":"102","author":"van Attekum","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.04.001_bib0004","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/14656566.2023.2218545","article-title":"An update on the efficacy of Venetoclax for chronic lymphocytic leukemia","volume":"24","author":"Lovell","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0005","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.2147\/OTT.S249586","article-title":"Ibrutinib in chronic lymphocytic leukemia: clinical applications, drug resistance, and prospects","volume":"13","author":"Zhou","year":"2020","journal-title":"OncoTargets Ther"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.04.001_bib0007","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3322\/caac.21235","article-title":"Cancer treatment and survivorship statistics, 2014","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.04.001_bib0008","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.592205","article-title":"Proliferative signals in chronic lymphocytic leukemia; what are we missing?","volume":"10","author":"Haselager","year":"2020","journal-title":"Front Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.001_bib0010","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","article-title":"CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease","volume":"13","author":"Pehlivan","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"issue":"10254","key":"10.1053\/j.seminhematol.2024.04.001_bib0011","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.04.001_bib0012","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","article-title":"Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial","volume":"29","author":"Houot","year":"2023","journal-title":"Nat Med"},{"issue":"7897","key":"10.1053\/j.seminhematol.2024.04.001_bib0013","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.04.001_bib0014","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1182\/blood-2023-179529","article-title":"Lisocabtagene maraleucel (liso-cel) in R\/R CLL\/SLL: 24-month median follow-up of TRANSCEND CLL 004","volume":"142","author":"Siddiqi","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2022.02.001","article-title":"Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned","volume":"108","author":"Can","year":"2022","journal-title":"Exp Hematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.04.001_bib0016","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.04.001_bib0017","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/2767-9764.CRC-22-0200","article-title":"Enhanced costimulatory signaling improves CAR T-cell effector responses in CLL","volume":"2","author":"Collins","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.04.001_bib0018","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.3390\/cells11142176","article-title":"CLL-derived extracellular vesicles impair T-cell activation and foster T-cell exhaustion via multiple immunological checkpoints","volume":"11","author":"B\u00f6ttcher","year":"2022","journal-title":"Cells"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.04.001_bib0019","doi-asserted-by":"crossref","first-page":"12688","DOI":"10.1182\/blood-2022-168800","article-title":"T-cell dysfunction in CLL can be alleviated by blocking sialic acid-binding Ig-like lectin 10 (Siglec-10) ligation","volume":"140","author":"Van Bruggen","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.04.001_bib0020","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.001_bib0021","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41375-023-01817-z","article-title":"Chronic lymphocytic leukemia presence impairs antigen-specific CD8+ T-cell responses through epigenetic reprogramming towards short-lived effectors","volume":"37","author":"Martens","year":"2023","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0022","unstructured":"Chronic Lymphocytic Leukemia - Cancer Stat Facts [Internet]. SEER. [cited 2024 Mar 4]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"issue":"7","key":"10.1053\/j.seminhematol.2024.04.001_bib0023","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells","volume":"115","author":"G\u00f6rg\u00fcn","year":"2005","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.001_bib0024","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2018885863","article-title":"Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy","volume":"134","author":"van Bruggen","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.04.001_bib0025","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2014-05-577122","article-title":"Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy","volume":"124","author":"Simonetti","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.04.001_bib0026","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood-2005-12-011213","article-title":"Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia","volume":"108","author":"Johnson","year":"2006","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.04.001_bib0027","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1182\/bloodadvances.2021004861","article-title":"Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia","volume":"5","author":"Kater","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.04.001_bib0028","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0029","article-title":"High-dimensional single-cell definition of CLL T cells identifies Galectin-9 as novel immunotherapy target","author":"Cid","year":"2023","journal-title":"bioRxiv"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.04.001_bib0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.humpath.2005.09.029","article-title":"The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"37","author":"Soma","year":"2006","journal-title":"Hum Pathol"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0031","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.exphem.2019.06.445","article-title":"Resistance to venetoclax in chronic lymphocytic leukaemia (CLL)","volume":"76","author":"Thijssen","year":"2019","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.001_bib0032","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3324\/haematol.2009.019133","article-title":"A novel subset of T-helper cells: follicular T-helper cells and their markers","volume":"95","author":"Laurent","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.04.001_bib0033","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.it.2021.04.006","article-title":"Cytokine-skewed Tfh cells: functional consequences for B cell help","volume":"42","author":"Olatunde","year":"2021","journal-title":"Trends Immunol"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.04.001_bib0034","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1182\/blood-2012-11-467670","article-title":"IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells","volume":"122","author":"Pascutti","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.001_bib0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.12401","article-title":"Enhancement of CD154\/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia","volume":"162","author":"Ahearne","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.04.001_bib0036","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2015-11-682997","article-title":"IL-4 rescues surface IgM expression in chronic lymphocytic leukemia","volume":"128","author":"Guo","year":"2016","journal-title":"Blood"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.04.001_bib0037","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1182\/blood-2015-11-682906","article-title":"IL-4 enhances expression and function of surface IgM in CLL cells","volume":"127","author":"Aguilar-Hernandez","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.04.001_bib0038","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41375-020-0873-2","article-title":"T-cells in chronic lymphocytic leukemia: guardians or drivers of disease?","volume":"34","author":"Roessner","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.001_bib0039","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1182\/blood.V89.3.941","article-title":"Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-\u03b2","volume":"89","author":"Douglas","year":"1997","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.001_bib0040","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.cell.2020.07.038","article-title":"il4i1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression","volume":"182","author":"Sadik","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.001_bib0041","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood-2006-07-036210","article-title":"Human IL4I1 is a secreted L-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation","volume":"110","author":"Boulland","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.001_bib0042","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2035117","article-title":"Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders \u2013 advances and challenges","volume":"18","author":"Goswami","year":"2022","journal-title":"Hum Vaccines Immunother"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.001_bib0043","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.001_bib0044","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.leukres.2010.08.010","article-title":"Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease","volume":"35","author":"D'Arena","year":"2011","journal-title":"Leuk Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.001_bib0045","first-page":"677","article-title":"Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia","volume":"20","author":"Giannopoulos","year":"2008","journal-title":"Oncol Rep"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.04.001_bib0046","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.immuni.2021.11.004","article-title":"Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity","volume":"54","author":"Hanna","year":"2021","journal-title":"Immunity"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.04.001_bib0047","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/s41375-021-01136-1","article-title":"EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia","volume":"35","author":"Roessner","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.001_bib0048","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/leu.2012.165","article-title":"Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function","volume":"27","author":"DiLillo","year":"2013","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0049","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1097942","article-title":"T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations","volume":"13","author":"Vlachonikola","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.001_bib0050","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1158\/1078-0432.CCR-14-3017","article-title":"Antigen selection shapes the T-cell repertoire in chronic lymphocytic leukemia","volume":"22","author":"Vardi","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.001_bib0051","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.4049\/jimmunol.158.3.1482","article-title":"Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia","volume":"158","author":"Serrano","year":"1997","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0052","doi-asserted-by":"crossref","unstructured":"Blanco G, Vardi A, Puiggros A, et al. Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL. Oncoimmunology. 7(6):e1432328.","DOI":"10.1080\/2162402X.2018.1432328"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.001_bib0053","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41375-018-0250-6","article-title":"Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues","volume":"33","author":"Hanna","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.04.001_bib0054","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41587-021-01021-3","article-title":"Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer","volume":"40","author":"Ouspenskaia","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.04.001_bib0055","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.3109\/10428194.2012.698277","article-title":"Chronic lymphocytic leukemia specific T-cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis","volume":"53","author":"te Raa","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.04.001_bib0056","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0145-2126(97)00152-5","article-title":"Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment","volume":"22","author":"Van den Hove","year":"1998","journal-title":"Leuk Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.001_bib0057","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V98.3.754","article-title":"Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers","volume":"98","author":"Gamadia","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.001_bib0058","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1182\/blood-2003-01-0182","article-title":"Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia","volume":"102","author":"Mackus","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.001_bib0059","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood-2013-08-518183","article-title":"CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia","volume":"123","author":"te Raa","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.04.001_bib0060","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/leu.2011.111","article-title":"Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL","volume":"25","author":"Hofbauer","year":"2011","journal-title":"Leukemia"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.04.001_bib0061","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00262-013-1473-z","article-title":"Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype","volume":"62","author":"G\u00f6thert","year":"2013","journal-title":"Cancer Immunol Immunother CII"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.001_bib0062","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2013-12-546416","article-title":"CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs","volume":"124","author":"Jitschin","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.001_bib0063","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12967-021-03136-2","article-title":"Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence","volume":"19","author":"Davis","year":"2021","journal-title":"J Transl Med"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.04.001_bib0064","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1073\/pnas.0901166106","article-title":"E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction","volume":"106","author":"Gorgun","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.001_bib0065","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.2009.00784.x","article-title":"Mechanisms of costimulation","volume":"229","author":"Sharpe","year":"2009","journal-title":"Immunol Rev"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.04.001_bib0066","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1084\/jem.165.2.302","article-title":"Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo","volume":"165","author":"Jenkins","year":"1987","journal-title":"J Exp Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.04.001_bib0067","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1158\/2326-6066.CIR-14-0161","article-title":"The immunological synapse","volume":"2","author":"Dustin","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.04.001_bib0068","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/mt.2015.4","article-title":"Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression","volume":"23","author":"Curran","year":"2015","journal-title":"Mol Ther"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0069","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1182\/blood-2021-152495","article-title":"Chronic lymphocytic leukemia actively induces T-cell dysfunction by contact-dependent signaling via CD24 and CD52","volume":"138","author":"Van Bruggen","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.04.001_bib0070","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood.2021013990","article-title":"Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment","volume":"140","author":"Chen","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.04.001_bib0071","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1084\/jem.20151159","article-title":"T cell metabolism drives immunity","volume":"212","author":"Buck","year":"2015","journal-title":"J Exp Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.001_bib0072","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev-immunol-042617-053019","article-title":"Unraveling the complex interplay between T cell metabolism and function","volume":"36","author":"Klein Geltink","year":"2018","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.04.001_bib0073","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41577-021-00537-8","article-title":"CD8+ T cell metabolism in infection and cancer","volume":"21","author":"Reina-Campos","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0074","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cophys.2020.07.016","article-title":"Calcium regulation of t cell metabolism","volume":"17","author":"Wang","year":"2020","journal-title":"Curr Opin Physiol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.04.001_bib0075","first-page":"2532","article-title":"Suppression of Glut1 and glucose metabolism by decreased Akt\/mTORC1 signaling drives T cell impairment in B cell leukemia","volume":"197","author":"Siska","year":"2016","journal-title":"J Immunol Baltim Md 1950"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0076","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2015.00001","article-title":"Glucose metabolism regulates T cell activation, differentiation, and functions","volume":"6","author":"Palmer","year":"2015","journal-title":"Front Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.001_bib0077","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41389-017-0011-9","article-title":"The hypoxic tumour microenvironment","volume":"7","author":"Petrova","year":"2018","journal-title":"Oncogenesis"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.001_bib0078","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/bloodadvances.2016000984","article-title":"Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment","volume":"1","author":"Serra","year":"2016","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0079","first-page":"1721","article-title":"Hyper-activation of the adenosinergic axis in the E\u03bc-TCL1 chronic lymphocytic leukemia mouse model offers therapeutic opportunities","volume":"130","author":"Vaisitti","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0080","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2023010305","article-title":"T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia","author":"Montironi","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.001_bib0081","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3324\/haematol.2019.242016","article-title":"Targeting the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia","volume":"106","author":"Arruga","year":"2020","journal-title":"Haematologica"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.04.001_bib0082","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/bloodadvances.2022007034","article-title":"Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells","volume":"6","author":"van Bruggen","year":"2022","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0083","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3389\/fimmu.2019.00925","article-title":"Targeting adenosine in cancer immunotherapy to enhance T-cell function","volume":"10","author":"Vigano","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.001_bib0084","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.immuni.2020.03.010","article-title":"Visualization of T cell migration in the spleen reveals a network of perivascular pathways that guide entry into T zones","volume":"52","author":"Chauveau","year":"2020","journal-title":"Immunity"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.001_bib0085","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.001_bib0086","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood.V66.3.614.614","article-title":"Interleukin 2 (IL 2) and interferon-gamma production by T lymphocytes from patients with B-chronic lymphocytic leukemia: evidence that normally released IL 2 is absorbed by the neoplastic B cell population","volume":"66","author":"Foa","year":"1985","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.04.001_bib0087","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3109\/10428194.2010.503820","article-title":"Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia","volume":"51","author":"Gonzalez-Rodriguez","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.04.001_bib0088","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bjh.13467","article-title":"Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model","volume":"170","author":"Gassner","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.04.001_bib0089","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3324\/haematol.2012.077537","article-title":"The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia","volume":"98","author":"Brusa","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.001_bib0090","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.leukres.2008.08.021","article-title":"Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade","volume":"33","author":"Pallasch","year":"2009","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0091","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594556","article-title":"Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia","volume":"11","author":"Griggio","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.001_bib0092","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12026-020-09146-4","article-title":"Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8+ T cells in early clinical stages of chronic lymphocytic leukemia","volume":"68","author":"Rezazadeh","year":"2020","journal-title":"Immunol Res"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.04.001_bib0093","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood-2017-06-792267","article-title":"Dual PD1\/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia","volume":"131","author":"Wierz","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.04.001_bib0094","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2015-02-626754","article-title":"Mechanisms of PD-L1\/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E\u00b5-TCL1 CLL mouse model","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.04.001_bib0095","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.04.001_bib0096","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.3390\/ijms22136648","article-title":"Evidence for non-cancer-specific T cell exhaustion in the Tcl1 mouse model for chronic lymphocytic leukemia","volume":"22","author":"Parigger","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.04.001_bib0097","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41419-024-06528-6","article-title":"Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia","volume":"15","author":"Boncompagni","year":"2024","journal-title":"Cell Death Dis"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.04.001_bib0098","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41592-021-01201-8","article-title":"High-throughput and single-cell T cell receptor sequencing technologies","volume":"18","author":"Pai","year":"2021","journal-title":"Nat Methods"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.001_bib0099","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1038\/s41467-019-11049-4","article-title":"High-throughput targeted long-read single cell sequencing reveals the clonal and transcriptional landscape of lymphocytes","volume":"10","author":"Singh","year":"2019","journal-title":"Nat Commun"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.04.001_bib0100","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/s41590-019-0544-5","article-title":"TCR sequencing paired with massively parallel 3\u2032 RNA-seq reveals clonotypic T cell signatures","volume":"20","author":"Tu","year":"2019","journal-title":"Nat Immunol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.04.001_bib0101","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ni.3799","article-title":"Genome-wide DNA-methylation landscape defines specialization of regulatory T cells in tissues","volume":"18","author":"Delacher","year":"2017","journal-title":"Nat Immunol"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.04.001_bib0102","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","article-title":"Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition","volume":"5","author":"Lew","year":"2021","journal-title":"Blood Adv"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.04.001_bib0103","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/bloodadvances.2020001956","article-title":"Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents","volume":"4","author":"Roeker","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.04.001_bib0104","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.3390\/ijms22115536","article-title":"Current state of CAR T-cell therapy in chronic lymphocytic leukemia","volume":"22","author":"Mancikova","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.04.001_bib0105","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.3390\/cancers12123837","article-title":"Overcoming the hurdles of autologous T-cell-based therapies in B-cell non-Hodgkin lymphoma","volume":"12","author":"van Bruggen","year":"2020","journal-title":"Cancers"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0106","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2024.01.001","article-title":"Transforming CLL management with immunotherapy: investigating the potential of CAR T-cells and bispecific antibodies","author":"Borogovac","year":"2024","journal-title":"Semin Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.001_bib0107","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3324\/haematol.2016.151100","article-title":"T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers","volume":"102","author":"Palma","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.001_bib0108","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/1078-0432.CCR-11-2630","article-title":"Expansion of a CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression","volume":"18","author":"Nunes","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.04.001_bib0109","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","article-title":"Inosine induces stemness features in CAR-T cells and enhances potency","volume":"42","author":"Klysz","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0110","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.876510","article-title":"A2A receptor contributes to tumor progression in P2\u00d77 null mice","volume":"10","author":"De Marchi","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.001_bib0111","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","article-title":"PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells","volume":"32","author":"Zheng","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.04.001_bib0112","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.2021011597","article-title":"PI3K\u03b4\/\u03b3 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0113","article-title":"Flexible and scalable control of T cell memory by a reversible epigenetic switch","author":"Abadie","year":"2023","journal-title":"bioRxiv"},{"key":"10.1053\/j.seminhematol.2024.04.001_bib0114","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-017-0227-4","article-title":"Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy","volume":"5","author":"Urak","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.04.001_bib0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/j.seminhematol.2020.07.005","article-title":"Improving CAR T cell therapy by optimizing critical quality attributes","volume":"57","author":"Reddy","year":"2020","journal-title":"Semin Hematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.04.001_bib0116","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1158\/2159-8290.CD-20-1677","article-title":"Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy","volume":"11","author":"Chen","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.001_bib0117","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41467-023-36126-7","article-title":"Enhancing CAR-T cell functionality in a patient-specific manner","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat Commun"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.04.001_bib0118","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.3390\/cancers14133230","article-title":"Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies","volume":"14","author":"Xie","year":"2022","journal-title":"Cancers"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632400057X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632400057X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T13:20:45Z","timestamp":1720531245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719632400057X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":117,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S003719632400057X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.04.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The complexities of T-cell dysfunction in chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}